Saturday, 25 Apr, 2026
Published: April 25, 2026, 12:26 PM
The new weapon against cancer? Photo: Collected
The 4,000-year-old drug most commonly found in household medicine cabinets is proving to be a formidable ally in the fight against cancer. Aspirin, traditionally used for pain relief and cardiovascular protection, is now being hailed as a major preventative measure against certain types of tumors.
Recent clinical trials and long-term studies have finally begun to shed light on how this inexpensive pill stops cancer from forming and spreading across the body, leading to significant changes in global health policies.
A landmark study led by John Burn, a professor of clinical genetics at Newcastle University, has provided compelling evidence regarding the drug’s efficacy. The research focused on patients with Lynch Syndrome, a genetic condition that predisposes individuals to a significantly higher risk of colorectal and other cancers.
One participant, Nick James, who carries the faulty gene, has remained cancer-free for over a decade while taking a daily dose of aspirin. Burn’s trial revealed that patients taking aspirin for at least two years saw their risk of colorectal cancer drop by nearly 50 percent.
While initial trials utilized a 600mg dose, more recent data under peer review suggest that a much lower daily dose of 75mg to 100mg could be just as effective.
This discovery is a game-changer for long-term treatment, as lower doses significantly reduce the risk of severe side effects such as internal bleeding, stomach ulcers, and brain hemorrhages. In the United Kingdom, these findings have already influenced official health guidelines. Since 2020, the National Health Service has recommended that individuals with Lynch Syndrome begin a regular aspirin regimen as early as age 20 to mitigate their lifetime cancer risk.
The historical trajectory of aspirin is equally fascinating. Archaeologists have traced its origins to 4,400-year-old Mesopotamian clay tablets describing remedies derived from the willow tree.
The modern synthesis of acetylsalicylic acid by Bayer in the late 19th century paved the way for its global ubiquity. However, it wasn`t until the 1970s that scientists first noticed its potential to prevent metastasis—the spread of cancer cells—in animal models. In 2010, Oxford University’s Peter Rothwell re-analyzed decades of cardiovascular data to confirm that aspirin indeed reduced both the incidence and spread of human cancers.
In Sweden, the surgical community has taken these findings a step further. Professor Anna Martling of the Karolinska Institute conducted a randomized controlled trial involving nearly 3,000 patients.
The study, published in September 2025, demonstrated that patients with specific genetic mutations who took 160mg of aspirin daily after surgery had less than half the risk of cancer recurrence. As of January 2026, Swedish hospitals have integrated genetic screening for these mutations into their standard protocol, offering low-dose aspirin to eligible bowel cancer patients.
Despite the growing enthusiasm, oncology experts stress that aspirin is not a "one-size-fits-all" solution. Its blood-thinning properties mean it must be taken strictly under medical supervision.
Ongoing large-scale trials, such as those led by Professor Ruth Langley at University College London, are currently examining whether aspirin can prevent the recurrence of breast, prostate, and gastroesophageal cancers. With results expected later in 2026 or 2027, the medical community remains hopeful that this ancient remedy will continue to reveal new ways to protect the modern world from its most feared diseases.
Design & Developed by 